[The first antidote is available]

MMW Fortschr Med. 2016 Jun 9;158(11):74. doi: 10.1007/s15006-016-8386-7.
[Article in German]
No abstract available

Publication types

  • Clinical Trial, Phase III

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Blood Loss, Surgical / prevention & control*
  • Dabigatran / adverse effects*
  • Dabigatran / antagonists & inhibitors*
  • Humans
  • Infusions, Intravenous

Substances

  • Antibodies, Monoclonal, Humanized
  • idarucizumab
  • Dabigatran